Verastem, Inc. (VSTM) 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers Verastem, Inc.'s Form 10-K for the fiscal year ended December 31, 2024. Verastem is a late-stage biopharmaceutical company focused on developing novel small molecule drugs targeting RAS/MAPK pathway-driven cancers. The company's primary pipeline consists of the combination of avutometinib (a RAF/MEK inhibitor) and defactinib (a FAK inhibitor) for the treatment of low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and pancreatic cancer. The company also holds options to license KRAS G12D inhibitor VS-7375 from GenFleet Therapeutics.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $10.0 million | $0.0 million |
| Net Loss | $(130.6) million | $(87.4) million |
| Research & Development Expenses | $81.3 million | $61.4 million |
| Selling, General & Administrative Expenses | $43.6 million | $30.7 million |
| Cash, Cash Equivalents & Investments | $88.8 million | $137.1 million |
| Accumulated Deficit | $(955.5) million | $(824.9) million |
| Long-Term Debt (Oxford Loan) | $40.7 million | $40.1 million |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product sales revenue from its core pipeline.
Material Changes vs. Prior Period
- Revenue: Revenue increased from $0 in 2023 to $10.0 million in 2024, driven entirely by a sales milestone payment received from Secura Bio, Inc. upon COPIKTRA achieving $100 million in worldwide net sales.
- Net Loss: Net loss widened by approximately $43.2 million year-over-year. This was primarily due to a $19.1 million non-cash mark-to-market loss on warrant liabilities issued in July 2024 and increased operating expenses.
- Operating Expenses: R&D expenses increased by $19.9 million, largely due to costs associated with the Phase 3 RAMP 301 trial and NDA submission activities. SG&A expenses increased by $12.9 million, driven by commercial readiness costs and financing fees.
- Liquidity: Cash and investments decreased by approximately $48.3 million, reflecting higher operating burn and investment maturities not fully reinvested.
Guidance, Outlook, and Risks
Regulatory Milestones: The FDA accepted Verastem's New Drug Application (NDA) for avutometinib and defactinib for recurrent KRAS mutant LGSOC under the accelerated approval pathway on December 30, 2024. The Prescription Drug User Fee Act (PDUFA) action date is set for June 30, 2025. The FDA stated it does not plan to hold an advisory committee meeting.
Commercial Outlook: The company is preparing for a potential mid-2025 launch in the U.S. and has entered a strategic collaboration with IQVIA to support commercialization. The company estimates a total annual incident addressable market of approximately $300 million for KRAS mutant LGSOC in the U.S.
Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months following the issuance of the financial statements. This is due to recurring losses and the need for additional capital to fund operations and clinical trials.
Recent Financing (Subsequent Event): On January 13, 2025, the company entered into a Note Purchase Agreement for up to $150 million in notes, initially selling $75 million. Proceeds were used to repay the existing Oxford Loan in full. The notes bear interest and include a revenue participation feature.
Risks: Key risks include the potential rejection of the NDA, failure of the confirmatory Phase 3 RAMP 301 trial, inability to secure additional funding, and the impact of the Section 382 ownership change limitations on the utilization of Net Operating Loss (NOL) carryforwards.
Investor Verification Checklist
- NDA Approval Status: Verify the FDA's decision on the NDA for avutometinib/defactinib by the June 30, 2025 PDUFA date.
- Cash Runway: Confirm the company's ability to fund operations through the NDA decision and potential launch, given the "substantial doubt" going concern disclosure.
- Debt Obligations: Review the terms of the new January 2025 Note Purchase Agreement, specifically the revenue participation percentage (1.0% to 2.0%) and interest rate caps.
- Section 382 Limitations: Assess the impact of the ownership change on the $370.6 million in federal NOL carryforwards, noting the company can currently only utilize approximately $1.6 million per year.
- GenFleet Option Exercise: Monitor the progress of the VS-7375 (KRAS G12D inhibitor) program following the $6.0 million option exercise payment made in January 2025.